Literature DB >> 15880209

[Percutaneous transluminal coronary angioplasty in a patient with idiopathic thrombocytopenic purpura].

Luis Gustavo M Marques1, Murillo Kenji Furukawa, Thenyson Pereira Leitão, José Luis A Quiñones, Fernando César de Queiroz, Rogerio Felippe Tiossi, Virgílio Ribeiro Franco, Carlos Eduardo M Domingues, Decio Salvadori.   

Abstract

The association between coronary heart disease and thrombocytopenic purpura is rare and poses some difficulties when myocardial revascularization is necessary. We report a case with this association and significant coronary impairment, which was percutaneously treated with stent implantation.

Entities:  

Mesh:

Year:  2005        PMID: 15880209     DOI: 10.1590/s0066-782x2005000400012

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  4 in total

Review 1.  Retention of atherogenic lipoproteins in atherogenesis.

Authors:  M Gustafsson; C Flood; P Jirholt; J Borén
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 2.  Primary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. A case report and review of the literature.

Authors:  Aleksandar N Neskovic; Ivan Stankovic; Predrag Milicevic; Aleksandar Aleksic; Alja Vlahovic-Stipac; Branko Calija; Biljana Putnikovic
Journal:  Herz       Date:  2010-02-09       Impact factor: 1.443

Review 3.  Two cases and review of the literature: primary percutaneous angiography and antiplatelet management in patients with immune thrombocytopenic purpura.

Authors:  Estelle Torbey; Harout Yacoub; Donald McCord; James Lafferty
Journal:  ISRN Hematol       Date:  2013-12-29

Review 4.  Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.

Authors:  Ge Li-Sha; Chen Peng; Li Yue-Chun
Journal:  BMC Cardiovasc Disord       Date:  2015-09-18       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.